This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yeo, W. Articles by Johnson, P. J. Search for Related Content PubMed PubMed Citation Articles by Yeo, W. Articles by Johnson, P. J. Social Bookmarking                            What's this?

Lamivudine for the Prevention of Hepatitis B Virus Reactivation in Hepatitis B s-Antigen Seropositive Cancer Patients Undergoing Cytotoxic Chemotherapy

From the Department of Clinical Oncology and Department of Microbiology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong

Address reprint requests to Winnie Yeo, MD, MRCP, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong; e-mail: winnieyeo{at}cuhk.edu.hk

PURPOSE: For cancer patients receiving cytotoxic chemotherapy, hepatitis B virus (HBV) reactivation is a well described complication resulting in varying degrees of liver damage. The objectives of this study were to assess the efficacy of the antiviral agent lamivudine in reducing the incidence of HBV reactivation and diminishing morbidity and mortality of cancer patients with chronic HBV infection during chemotherapy.

PATIENTS AND METHODS: Two groups were compared in this nonrandomized study. The prophylactic lamivudine group consisted of 65 patients in a phase II study who were treated with lamivudine before and until 8 weeks after discontinuing chemotherapy. The historical controls consisted of 193 consecutive patients who underwent chemotherapy without prophylactic lamivudine. Significant prognosticators for the development of HBV reactivation were determined based on data from the controls. Potential confounding factors were identified between the two groups. The outcomes were compared.

RESULTS: In the controls, lymphoma and anthracycline usage were factors identified to be associated with reactivation. The two groups were comparable in most baseline characteristics, although in the prophylactic lamivudine group, there were significantly more patients with lymphoma and receiving anthracyclines. In the prophylactic lamivudine group, there was significantly less HBV reactivation (4.6% v 24.4% in the controls; P < .001), fewer incidences of hepatitis (17.5% v 44.6%; P < .0001) that were less severe (4.8% v 18.7%; P = .0005), and less disruption of chemotherapy (15.4% v 34.6%; P = .0029). The reduction in overall mortality was not statistically different.

CONCLUSION: Prophylactic lamivudine significantly reduced the incidence of HBV reactivation and the overall morbidity of cancer patients undergoing chemotherapy.

Supported in part by GlaxoWellcome Ltd, Hong Kong.

Presented in part at the 2002 American Society of Clinical Oncology Annual Meeting, May18-21, 2002, Orlando, FL.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Y. X. Koo, D. S.W. Tan, B. H. Tan, R. Quek, M. Tao, and S. T. Lim Risk of Hepatitis B Virus Reactivation in Patients Who Are Hepatitis B Surface Antigen Negative/Antibody to Hepatitis B Core Antigen Positive and the Role of Routine Antiviral Prophylaxis J. Clin. Oncol., May 20, 2009; 27(15): 2570 - 2571. [Full Text] [PDF]

				R. Liang How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation Blood, April 2, 2009; 113(14): 3147 - 3153. [Abstract] [Full Text] [PDF]

				W. Yeo, T. C. Chan, N. W.Y. Leung, W. Y. Lam, F. K.F. Mo, M. T. Chu, H. L.Y. Chan, E. P. Hui, K. I.K. Lei, T. S.K. Mok, et al. Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab J. Clin. Oncol., February 1, 2009; 27(4): 605 - 611. [Abstract] [Full Text] [PDF]

				R. Loomba, A. Rowley, R. Wesley, T. J. Liang, J. H. Hoofnagle, F. Pucino, and G. Csako Systematic Review: The Effect of Preventive Lamivudine on Hepatitis B Reactivation during Chemotherapy Ann Intern Med, April 1, 2008; 148(7): 519 - 528. [Abstract] [Full Text] [PDF]

				M. G. Chheda, J. Drappatz, N. J. Greenberger, S. Kesari, S. E. Weiss, D. C. Gigas, L. M. Doherty, and P. Y. Wen Hepatitis B reactivation during glioblastoma treatment with temozolomide: A cautionary note Neurology, March 20, 2007; 68(12): 955 - 956. [Full Text] [PDF]

				M. Sandherr, H. Einsele, H. Hebart, C. Kahl, W. Kern, M. Kiehl, G. Massenkeil, O. Penack, X. Schiel, S. Schuettrumpf, et al. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO) Ann. Onc., July 1, 2006; 17(7): 1051 - 1059. [Abstract] [Full Text] [PDF]

				R. J. Firpi and D. R. Nelson Viral Hepatitis: Manifestations and Management Strategy Hematology, January 1, 2006; 2006(1): 375 - 380. [Abstract] [Full Text] [PDF]

				C-K Hui, W W W Cheung, W-Y Au, A K W Lie, H-Y Zhang, Y-H Yueng, B C Y Wong, N Leung, Y-L Kwong, R Liang, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy Gut, November 1, 2005; 54(11): 1597 - 1603. [Abstract] [Full Text] [PDF]

				W. Yeo, T. S. Mok, B. Zee, T. W. T. Leung, P. B. S. Lai, W. Y. Lau, J. Koh, F. K. F. Mo, S. C. H. Yu, A. T. Chan, et al. A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon {alpha}-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma J Natl Cancer Inst, October 19, 2005; 97(20): 1532 - 1538. [Abstract] [Full Text] [PDF]